The therapeutic potential of Bcl-2/Bcl-xL inhibitors in diabetes emerged in 2019, when two complementary studies introduced the use of BH3 mimetics as senolytic compounds, which are drugs that selectively induce apoptosis in senescent cells [195,208]. The gene discussed is BCL2; the disease is diabetes mellitus.